Israel Englander Regeneron Pharmaceuticals, Inc. Call Options Transaction History

Millennium Management LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 14, 2024	SELL	$1024.09 - $1201.76 $32 Million - $37.5 Million	-31,200 Reduced 73.07%	11,500 $12.1 Million
Q2 2024 Aug 14, 2024	SELL	$883.2 - $1071.19 $16 Million - $19.4 Million	-18,100 Reduced 29.77%	42,700 $44.9 Million
Q1 2024 May 15, 2024	SELL	$902.69 - $993.35 $12.8 Million - $14.1 Million	-14,200 Reduced 18.93%	60,800 $58.5 Million
Q4 2023 Feb 14, 2024	SELL	$775.18 - $881.7 $775,180 - $881,700	-1,000 Reduced 1.32%	75,000 $65.9 Million
Q2 2023 Aug 14, 2023	BUY	$700.03 - $830.35 $48.9 Million - $58 Million	69,800 Added 1125.81%	76,000 $54.6 Million
Q1 2023 May 15, 2023	SELL	$680.49 - $826.97 $18.7 Million - $22.7 Million	-27,500 Reduced 81.6%	6,200 $5.09 Million
Q4 2022 Feb 14, 2023	BUY	$705.89 - $766.39 $352,945 - $383,195	500 Added 1.51%	33,700 $24.3 Million
Q3 2022 Nov 14, 2022	BUY	$573.97 - $724.32 $6.89 Million - $8.69 Million	12,000 Added 56.6%	33,200 $22.9 Million

1,512

82.6M

1.22M

1.51M

Ticker REGN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 107,190,000
Market Cap $73.7B
Description
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; and diabetic retinopathy, as well as macula...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.